Israel’s MigVax, the affiliate company established by Israeli scientists at the Migal Galilee Research Institute to develop a vaccine for the coronavirus, has received a $4.3 million award from Norway’s Coalition of Epidemic Preparedness Innovations (CEPI) to help support the initial development of its COVID-19 oral subunit vaccine tablet.

Read more here.